Durect (DRRX) Gets a Buy Rating from H.C. Wainwright

By Jason Carr

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Durect (DRRXResearch Report), with a price target of $5.50. The company’s shares closed last Tuesday at $2.55.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 21.0% and a 46.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

Durect has an analyst consensus of Strong Buy, with a price target consensus of $5.25, representing an 112.6% upside. In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.95 and a one-year low of $0.50. Currently, Durect has an average volume of 904K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.